IGF2BP2, EIF4A1 and their targets could serve as potential biomarkers and therapeutic targets for ESCC, offering promising novel approaches for the diagnosis and treatment of ESCC. This evidence concerns the gene EIF4A1 and esophageal squamous cell carcinoma.